Vom Potenzial der Integrativen Medizin

Unsere Gesprächspartnerinnen: Frau Dr. med. Petra Voiß und Frau Dr. phil. Petra Klose

Publication History

Article published online:
24 June 2021

• Literatur

• 1 Drozdoff L, Klein E, Kiechle M. et al. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med 2018; 18: 259
• 2 Grimm D, Mathes S, Woelber L. et al. Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany. Arch Gynecol Obstet 2021; 303: 1315-1330.
• 3 Keene MR, Heslop IM, Sabesan SS, Glass BD. Complementary and alternative medicine use in cancer: A systematic review. Complement Ther Clin Pract 2019; 35: 33-47
• 4 Fremd C, Hack CC, Schneeweiss A. et al. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Arch Gynecol Obstet 2017; 295: 1239-1245
• 5 Corina G, Christine H, Klein G. Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis. Support Care Cancer 2016; 24: 3857-3862
• 6 Paepke D, Wiedeck C, Hapfelmeier A. et al. Prevalence and predictors for nonuse of complementary medicine among breast and gynecological cancer patients. Breast Care (Basel) 2020; 15: 380-385
• 7 Grimm D, Voiss P, Paepke D. et al. Gynecologists’ attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. Arch Gynecol Obstet 2021; 303: 967-980
• 8 Koenig CJ, Ho EY, Trupin L. et al. An exploratory typology of provider responses that encourage and discourage conversation about complementary and integrative medicine during routine oncology visits. Patient Educ Couns 2015; 98: 857-863
• 9 Samuels N, Ben-Arye E, Maimon Y. et al. Unmonitored use of herbal medicine by patients with breast cancer: reframing expectations. J Cancer Res Clin Oncol 2017; 143: 2267-2273
• 10 Haidinger R, Bauerfeind I. Long-term side effects of adjuvant therapy in primary breast cancer patients: Results of a web-based survey. Breast Care (Basel) 2019; 14: 111-116
• 11 Doege D, Thong MS, Koch-Gallenkamp L. et al. Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany. Breast Cancer Res Treat 2019; 175: 499-510
• 12 Haller H, Choi KE, Lange S, Kümmel S, Paul A, Cramer H, Dobos G, Voiss P. Effects of an integrative mind-body-medicine group program on breast cancer patients during chemotherapy: An observational study. Curr Pharm Des 2021; 27: 1112-1120
• 13 Jung AY, Cai X, Thoene K. et al. Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy. Am J Clin Nutr 2019; 109: 69-78
• 14 Ambrosone CB, Zirpoli GR, Hutson AD. et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J Clin Oncol 2020; 38: 804-814
• 15 Jermini M, Dubois J, Rodondi PY. et al. Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci Rep 2019; 9: 5078